FDA requests market withdrawal of all ranitidine products

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1799卷 / 1期

关键词：

D O I：

10.1007/s40278-020-77006-4

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：4 / 4

相关论文

共 50 条

[1] FDA requests withdrawal of lorcaserin from US market
Reactions Weekly, 2020, 1792 (1) : 1 - 1
[2] FDA REQUESTS WITHDRAWAL OF WEIGHT-LOSS DRUG FROM MARKET
Aschenbrenner, Diane S.
AMERICAN JOURNAL OF NURSING, 2020, 120 (05) : 22 - 23
[3] US FDA requests voluntary withdrawal of bacitracin for injection
Reactions Weekly, 2020, 1791 (1) : 5 - 5
[4] Impurity Testing of Ranitidine Products: US FDA Update
不详
PHARMACEUTICAL MEDICINE, 2020, 34 (01) : 70 - 70
[5] Impurity testing of ranitidine products: US FDA update
Reactions Weekly, 2019, 1779 (1) : 1 - 1
[6] FDA requests label changes for all sleep disorder medications
Naccari, Christopher
CNS SPECTRUMS, 2007, 12 (04) : 262 - 262
[7] FDA's CDER proposes market withdrawal of hydroxyprogesterone
Reactions Weekly, 2020, 1826 (1) : 3 - 3
[8] US FDA recommends LC-HRMS for testing ranitidine products
Reactions Weekly, 2019, 1774 (1) : 6 - 6
[9] CIMETIDINE USE IN US: EFFECTS OF FDA WITHDRAWAL OF RANITIDINE AND COVID-19 PANDEMIC
Balaban, David H.
McNamara, Sherrie
Galt, Deborah J.
GASTROENTEROLOGY, 2021, 160 (06) : S449 - S449
[10] Ranitidine: all products are out of stock as investigations continue
Mahase, Elisabeth
BMJ-BRITISH MEDICAL JOURNAL, 2019, 367 : l6746

← 1 2 3 4 5 →